Cancer incidence in Spain, 2015

Clinical and Translational Oncology

Volumn 19, Issue 7, 2017, Pages 799-825

  Galceran, J ^a,b   Ameijide, A ^a   Carulla, M ^a   Mateos, A ^c   Quiros J R ^d   Rojas, D ^e   Aleman A ^d   Torrella, A ^f   Chico, M ^c   Vicente, M ^g   Diaz J M ^c   Larranaga N ^h,i   Marcos Gragera, R ^j,k   Sanchez M J ^i,l   Perucha, J ^m   Franch, P ⁿ   Navarro, C ^i,o,p   Ardanaz, E ^i,q   Bigorra, J ^a   Rodrigo, P ^r   Bonet, R Peris ^s   Almar, Enrique ^t   Argüelles, Marcial V ^t   Sabater, Consol ^t   Botella, Paloma ^t   Ripoll, María ^t   Díaz, Cristina ^t   Fuster, Nieves ^t   Jiménez, Rosario ^t   Navarro, Ana Isabel Marcos ^t   Bidaurrazaga, Joseba ^t   Lopez de Munain, Arantza ^t   Izquierdo, Àngel ^t   Vilardell, Loreto ^t   Molina Portillo, Elena ^t   Rodríguez Barranco, Miguel ^t   Ramos, Maria ^t   Navarro, Carmen ^t   Chirlaque, María Dolores ^t   Salmerón, Diego ^t   Guevara, Marcela ^t   Burgui, Rosana ^t   Pardo, Elena ^t   more..

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c Health and Social Welfare Authority   (Spain)

^d Public Health Dir   (Spain)

^e Canary Islands Government   (Spain)

^f Epidemiology Unit   (Spain)

^g and FISABIO   (Spain)

^h DEPARTMENT OF HEALTH   (Spain)

ⁱ CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^j GENERALITAT DE CATALUNYA   (Spain)

^k UNIVERSITY OF GIRONA   (Spain)

^l UNIVERSITY OF GRANADA   (Spain)

^m La Rioja Cancer Registry   (Spain)

ⁿ Mallorca Cancer Registry   (Spain)

^o DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^p UNIVERSITY OF MURCIA   (Spain)

^q IdiSNA Navarra Institute for Health Research   (Spain)

^r INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^s UNIVERSITY OF VALENCIA   (Spain)

^t NONE

more..

Author keywords

Cancer; Cancer cases; Cancer statistics; Incidence; Spain; Trends

Indexed keywords

ARTICLE; BILIARY TRACT CANCER; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CHILDHOOD CANCER; COLORECTAL CANCER; ESOPHAGUS CANCER; GALLBLADDER CANCER; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIP CANCER; LIVER CANCER; LUNG CANCER; MOUTH CANCER; MYELOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PHARYNX CANCER; PROSTATE CANCER; SKIN CANCER; SPAIN; STOMACH CANCER; TESTIS CANCER; THYROID CANCER; TREND STUDY; TUMOR INVASION; UTERUS CANCER; ADOLESCENT; ADULT; AGE; AGED; CHILD; FEMALE; INCIDENCE; INFANT; MALE; MIDDLE AGED; NEOPLASM; NEWBORN; PRESCHOOL CHILD; REGISTER; STATISTICS AND NUMERICAL DATA; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; SPAIN; TIME FACTORS; YOUNG ADULT;

EID: 85009723276     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-016-1607-9     Document Type: Article

References (86)

1. Instituto Nacional de Estadística. Defunciones según la Causa de Muerte. Madrid: Instituto Nacional de Estadística. 2014 [updated 2016]. http://www.ine.es/jaxi/Tabla.htm?path=/t15/p417/a2014/l0/&file=01004.px&L=0. Accessed 3 Oct 2016.
2. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration: principles and methods. Lyon: IARC Sci Publ No. 95; 1991.
3. Moreno V, González JR, Soler M, Bosch FX, Kogevinas M, Borràs JM. Estimación de la incidencia de cáncer en España: período 1993–1996. Gac Sanit. 2001;15(5):380–8.
4. López-Abente G, Pollán M, Aragonés N, Pérez B, Gómez B, Hernández Barrera V, et al. Situación del cáncer en España: Incidencia. An Sist Sanit Navar. 2004;27(2):165–73.
5. Sanchez MJ, Payer T, de Angelis R, Larrañaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;21(Suppl 3):iii30–6.
6. International Agency for Research on Cancer. EUCAN. Lyon: International Agency for Research on Cancer [updated 2012]. http://eco.iarc.fr/EUCAN/Default.aspx. Accessed 3 Oct 2016.
7. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr.
8. Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, Peris-Bonet R, et al. Population-based cancer registries in Spain and their role in cancer control. Ann Oncol. 2010;21(Suppl 3):iii3–13.
9. World Health Organization. International Statistical classification of diseases and related health problems. 10th revision. Geneva: WHO; 1992.
10. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38(1):99–166.
11. Møller B, Fekjær H, Hakulinen T, Sigvaldason H, Storm HH, Talbäck M, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22:2751–66.
12. R Core Team. 2013. http://cran.r-project.org/web/packages/BRugs/index.html; http://cran.r-project.org/web/packages/R2WinBUGS/index.html; http://www.openbugs.net. Accessed 3 Oct 2016.
13. Rapiti E, Guarnori S, Pastoors B, Miralbell R, Usel M. Planning for the future: cancer incidence projections in Switzerland up to 2019. BMC Public Health. 2014;14:102.
14. Rébillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A, et al. Incidence and mortality of urological cancers in 2012 in France. Prog Urol. 2013;23(Suppl 2):S57–65.
15. Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M. Cancer screening in Spain. Ann Oncol. 2010;21(Suppl 3):iii43–51.
16. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. Lyon, France: IARC Sci Publ 155; (2002) http://www.iarc.fr/en/publications/pdfs-online/epi/sp155/.
17. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents, vol IX. Lyon, France: IARC Sci Publ 160; (2007) http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/.
18. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al., editors. Cancer incidence in five continents, vol. X (electronic version) Lyon: IARC; (2013) http://ci5.iarc.fr. Accessed 6 June 2016 (printed version: IARC Scientific Publication No. 164, 2014).
19. Bashir S, Estève J. Analysing the difference due to risk and demographic factors for incidence or mortality. Int J Epidemiol. 2000;29(5):878–84.
20. Peris R, Felipe S, Valero S, Pardo E. Cáncer infantil en España. Estadísticas 1980–2014. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2015. http://www.uv.es/rnti/informes.html (Edición Preliminar, CD-Rom).
21. Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999–2007: results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217–30.
22. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
23. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Tobacco Smoke and Involuntary Smoking, vol. 83. Lyon: IARC; 2004.
24. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Ionizing radiation, part 1: X- and gamma-radiation, and neutrons, vol. 75. Lyon: IARC; 2000.
25. Büchner FL, Bueno-de-Mesquita HB, Ros MM, Overvad K, Dahm CC, Hansen L, et al. Variety in fruit and vegetable consumption and the risk of lung cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev. 2010;19(9):2278–86.
26. Instituto Nacional de Estadística (INE). Encuesta Nacional de Salud de España. Estudios nacionales de consumo de tabaco 1978–1982. (1978).
27. Instituto Nacional de Estadística (INE). Encuesta Nacional de Salud 2011–12. [Internet]. Madrid: INE; 2013. http://www.ine.es/metodologia/t15/t153041912.pdf.
28. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomark Prev. 2009;18(2):541–50.
29. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents, vol 100B. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php.
30. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155–64.
31. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control. 1997;8:346–55.
32. Bosetti C, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005. Ann Oncol. 2007;18:431–46.
33. Mannetje A, Kogevinas M, Chang-Claude J, Cordier S, Gonzalez CA, Hours M, et al. Occupation and bladder cancer in European women. Cancer Causes Control. 1999;10:209–17.
34. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part C: arsenic, metals, fibres, and dusts, vol 100C. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php.
35. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health. 2001;25(4):263–70.
36. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Alcohol drinking, vol 38. Lyon: IARC; 1988. http://monographs.iarc.fr/ENG/Monographs/vol1-42/mono38.pdf.
37. World Cancer Research Fund/American Institute for Cancer Research (AICR). Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007. http://discovery.ucl.ac.uk/4841/.
38. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.
39. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114(6):1169–79.
40. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—part C: metals, arsenic, dusts, and fibres. Lancet Oncol. 2009;10(5):453–4.
41. Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis. 2010;28(4–5):600–3.
42. López-Abente G, Ardanaz E, Torrella-Ramos A, Mateos A, Delgado-Sanz D, Chirlaque MD, For the Colorectal Cancer Working Group. Changes in colorectal cancer incidence and mortality trends in Spain. Ann Oncol. 2010;21(Suppl 3):iii76–82.
43. Winawer SJ. Natural history of colorectal cancer. Am J Med. 1999;106(1A):3S–6S.
44. World Cancer Research Fund/American Institute for Cancer Research (AICR). Continuous update project. Colorectal cancer report 2010 summary. Food, nutrition, physical activity and the prevention of cancer [Internet]. AICR; 2011. http://www.dietandcancerreport.org/cancer_resource_center/downloads/cu/CUP_CRC_summary_2011.pdf.
45. Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11(7):579–88.
46. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958–72.
47. Hooker CM, Gallicchio L, Genkinger JM, Comstock GW, Alberg AJ. A prospective cohort study of rectal cancer risk in relation to active cigarette smoking and passive smoke exposure. Ann Epidemiol. 2008;18:28–35.
48. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13.
49. García A, Marzo M, Mascort J, Quintero E, García-Alfonso P, López-Ibor C, et al. Prevención del cáncer colorectal. Aten Primaria. 2009;41(3):127–8.
50. Red de Programas de Cribado de Cáncer. Situación de los Programas de Cribado de Cáncer Colorrectal en España. Red de Programas de Cribado de Cáncer. XV Reunión anual. Pamplona, junio 2012. http://www.programascancerdemama.org/images/archivos/SituacionColon%202012.pdf.
51. International Agency for Research on Cancer. IARC monographs on the evaluation of carginogenic risks to humans. A review of human carcinogens. Part E: personal habits and indoor combustions, vol 100E. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100E/.
52. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51(6):849–52.
53. Tascilar M, van Rees BP, Sturm PD, Tytgat GN, Hruban RH, Goodman SN, et al. Pancreatic cancer after remote peptic ulcer surgery. J Clin Pathol. 2002;55(5):340–5.
54. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.
55. Cabanes A, Pérez-Gómez B, Aragonés N, Pollán M, López-Abente G. La situación del cáncer en España, 1975–2006. Madrid: Instituto de Salud Carlos III; 2009.
56. Reeves GK, Pirie K, Green J, Bull D. Beral V; Million Women Study Collaborators. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer. 2009;100(3):538–44.
57. Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006.
58. Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res. 2008;14(9):2861–9.
59. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996;54(3 Suppl):1S–106S.
60. Benet Rodríguez M, Carvajal García-Pando A, García del Pozo J, Alvarez Requejo A, Vega Alonso T. Hormonal replacement therapy in Spain. Med Clin (Barc). 2002;119(1):4–8.
61. World Cancer Research Fund/American Institute for Cancer Research (AICR). Continuous update project report summary. Food, nutrition, physical activity and the prevention of breast cancer [Internet]. AICR; 2010. http://www.dietandcancerreport.org/cancer_resource_center/downloads/cu/cu_breast_cancer_report_2008_summary.pdf.
62. Red de Programas de Cribado de Cáncer; 2013. http://www.programascancerdemama.org/images/archivos/Indicadores_proceso_resultados_2011.pdf.
63. Pollán M, Michelena MJ, Ardanaz E, Izquierdo A, Sánchez-Pérez MJ, Torrella A. Breast Cancer Working Group. Breast cancer incidence in Spain before, during and after the implementation of screening programmes. Ann Oncol. 2010;21(Suppl 3):iii97–102.
64. Puig-Vives M, Pollan M, Rue M, Osca-Gelis G, Saez M, Izquierdo A, et al. Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983–2007. Breast. 2012;21(5):646–51.
65. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–91.
66. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part A: pharmaceuticals, vol. 100A. Lyon: IARC; 2012.
67. Kohlmann W, Gruber SB. Lynch síndrome [Internet]. En: Pagon RA, Bird TD, Dolan CR et al, editores. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 2004. http://www.ncbi.nlm.nih.gov/books/NBK1211/.
68. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–14.
69. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.
70. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103(3):1122–9.
71. Larrañaga N, Galceran J, Ardanaz E, Franch P, Navarro C, Sánchez MJ, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol. 2010;21(Suppl 3):iii83–9.
72. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol Rev. 2001;23(1):19–23.
73. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risc factor for prostate cancer. A meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100:693–701.
74. Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014;202:27–37.
75. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52.
76. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas—an update. J Intern Med. 2008;264(6):514–27.
77. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part F: chemical agents and related occupations, vol 100F. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100F/.
78. Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sánchez MJ, Garau I, For the Non-Hodgkin’s Lymphoma Working Group. Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3):iii90–6.
79. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822–6.
80. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355(9199):165–9.
81. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part D: radiation, vol 100D. Lyon: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100D/.
82. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.
83. Clark LN, Shin DB, Troxel AB, Khan S, Sober AJ, Ming ME. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol. 2007;56(5):768–73.
84. Ocaña-Riola R, Martínez-García C, Serrano S, Buendia-Eisman A, Ruiz-Baena C, Canela-Soler J. Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985–1992. Eur J Epidemiol. 2001;17(2):169–74.
85. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control. 2001;12(1):69–82.
86. Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.